This is the authors' abstract. We don't add key points for this paper.
Sacituzumab-govitecan (Sgov) is a new antibody-drug conjugate recently approved for metastatic triple negative breast cancer (mTNBC), so there are still few data published in the real-world setting.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Madroñal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: